Calendar

Cloudflare’s pre-event estimates were $0.34 EPS and $736.8M revenue, and its prior EPS beat streak and AI/network product exposure are supportive, but Oct. 30 shares fell 9.54% on 1.6x normal volume amid a broad technology selloff. The sharp negative tape contradicts the required recent price-strength signal; the checked sources did not establish positive estimate revisions or revenue upside.

Analyst EPS estimates have edged upward over 90 days and Airbnb guided to mid-teens Q3 gross-booking-value growth, but the stock declined across the last several sessions, recent closes were far from session highs, and no qualifying volume spike or verified revenue-revision upside emerged.

The $0.30 whisper against $0.29 consensus and strong reported international sales growth support a plausible positive surprise, but current-quarter revenue growth alone does not establish revenue upside versus consensus; volume was below the 1.5x threshold and recent close-location and sector-tape confirmation were insufficient.

EOG has a positive whisper gap and recent price strength, with a close near the session high on Oct. 29 and an established operating business. However, the supplied Nov. 5 earnings date conflicts with company investor-relations material scheduling the Q3 results call for Nov. 6; the date is therefore not reliably confirmed. Recent volume also did not reach 1.5x normal.

EPS estimates have moved modestly higher and recent results and AI-optics demand support momentum, but the latest session reversed sharply on heavy trading as semiconductor-sector weakness intensified; the pre-event tape does not satisfy the screen’s close-location and sector-health requirements.

Recent one-month EPS and three-month revenue estimate revisions are positive, while the stock gained about 2.9% over five sessions and closed near its daily high on elevated volume. The setup is tempered by negative three-month EPS revisions, prior-quarter EPS misses, and inconsistent third-party EPS estimates; treat as a watchlist, not a high-conviction surprise call.

The clinical testing business has visible growth and the stock showed a recent rebound, but the checked current-quarter EPS revisions were not positive and revenue revisions were essentially flat over one month; the near-term upside-surprise signal is therefore insufficient despite a supportive business narrative.

Devon has a modestly constructive near-term EPS revision signal and its latest quarter showed production and cash-flow strength, but revenue estimates have softened over three months and recent turnover does not establish accumulation above the required threshold. The available tape shows a strong latest close location, but the full required revenue, volume, and sector checks are not confirmed.

TEAM has a positive published whisper gap ($1.48 versus $1.39 consensus), a recent EPS beat history, and strong cloud-related company guidance. But its shares fell about 15.8% over five sessions, closed near the bottom of the latest session, and heavy recent turnover occurred during declines; revenue guidance is essentially in line with the cited consensus rather than a clear upside surprise indicator.

ED's November 5 after-close date is confirmed by Con Edison, and the available sources provide credible EPS and revenue consensus; however, no positive estimate-revision or revenue-upside signal was found. The stock's 5-session return was modestly positive, but recent closes were not near session highs and volume did not exceed 1.5x the recent average.

Microchip's checked whisper number is modestly above consensus, and management described recovering demand and sequential sales growth; however, the semiconductor tape was sharply weak and the required recent price, close-location, and volume signals were not verified.

Live Nation's investor-relations calendar confirms the event, and its latest report cited robust concert demand and higher deferred revenue; checked estimates provide consensus but no positive revision or whisper signal, while tape and volume requirements remain unverified and state antitrust litigation remains a risk.

Arm's Q1 results and Q2 revenue guidance point to continuing AI/data-center demand, but guidance near consensus is not itself a positive surprise indicator. The company IR calendar confirms Nov. 4, not the supplied Nov. 5 date; checked results did not establish a recent positive revision, volume accumulation, or qualifying close location.

Moderna's shares rebounded sharply during the five sessions through Oct. 30, but the checked earnings preview expects lower year-over-year EPS and revenue, with no positive EPS revision or revenue-upside signal verified. The close location in each of the latest three sessions and recent volume multiples failed to establish the required tape confirmation; ongoing losses and a revenue decline make this an incomplete setup.

BAM has a confirmed Nov. 6 results call, positive year-over-year analyst consensus and recent strength, while its latest filing described fee-bearing capital inflows and higher management fees. However, the checked sources did not establish positive estimate revisions or a revenue upside signal, and recent volume did not confirm accumulation; this is not a qualifying surprise setup.

Humana's Q3 EPS consensus was revised 2.23% lower over 30 days and its consensus points to a loss; reported revenue growth is not evidence of positive estimate revisions. Recent stock action was weak, recent volumes did not show a 1.5x burst, and the company had cut GAAP EPS guidance in July while affirming adjusted EPS guidance.

Vistra has reported estimates that imply year-over-year growth and a Zacks article describes a positive recent EPS-estimate revision, but available sources conflict materially on the quarter’s EPS and revenue outlook. The last verified price close was down on October 30, and recent close-location, volume accumulation, and XLU-relative strength were not established; the surprise case is not reliable enough to qualify.